Anti-FAP CAR T Cells Produced In Vivo Reduce Fibrosis and Restore Liver Homeostasis in Metabolic Dysfunction-Associated Steatohepatitis

Researchers explored the antifibrotic potential of this in vivo–generated anti-fibroblast activation protein alpha (FAP) CAR T cell therapy in metabolic dysfunction–associated steatohepatitis.